Exhibit 99.1 LeMaitre Q3 2026 Financial Results BURLINGTON, MA, November 4, 2026
Exhibit 99.1 LeMaitre Q3 2026 Financial Results BURLINGTON, MA, November 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q3 2026:
Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%. EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was comprised of 7% price and 5% units. Gross margin of 71.7% was up 90 bps (vs. adjusted) due to higher ASPs and operational efficiencies. Operating expenses increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678 increased 7% versus 9/30/2025 while rep count increased 13% to 171. In October, the company acquired certain vascular assets from B. Braun for $19.2mm. These polyester and silver-coated grafts, valve cutters and vein strippers recorded sales of $9.4mm in 2025, all outside of North America. Sales will transition into LeMaitre’s channel over the next 18-24months as B. Braun’s customer contracts conclude or transfer to LeMaitre. During this transition, LeMaitre will receive a portion of the profits on B. Braun-originated sales. Chairman/CEO George LeMaitre said, “We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-countrysales force.” Business Outlook
The top- and bottom-line impacts of the newly acquired B. Braun * products are reflected in this Business Outlook. LeMaitre anticipates recording ~$150,000 of Q4 2026 B. Braun product sales and break-even operating income impact.
2025 results include a Q3 non-recurring benefit from the Employee ** Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP measures is included.
Quarterly Dividend On October 27, 2026, the Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on December 3, 2026, to stockholders of record on November 19, 2026. Share Repurchase Program On February 19, 2026, the Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.
Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company’s website at . Access to the live call is available by registering online . All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at . For individuals unable to join the live conference call, a replay will be available on the Company’s website.
A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.
In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for Q3 2026 operating income, gross margin, operating expense and EPS, as well as operating income and EPS guidance, adjusted to exclude the effects of the employee retention tax credit received in 2025. Management believes that viewing growth in these measures excluding those effects provides an alternative and meaningful view of the Company’s profitability.
Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
The Company’s current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other regulatory reviews, affecting our ability to market and sell our products domestically and internationally; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; competition from other medical device companies and alternative medical technologies; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of
litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands)
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -unaudited Assets Current assets: Cash and cash $ 27,493 $ 28,244 equivalents Short-term marketable 362,228 330,876 securities Accounts receivable, 35,876 33,610 net Inventory and other deferred 71,272 70,422 costs Prepaid expenses and 8,642 5,080 other current assets Total current 505,511 468,232 assets Property and 30,465 26,997 equipment, net Right-of-use 18,503 15,762 leased assets Goodwill 65,945 65,945 Other intangibles, 29,295 33,089 net Deferred tax 746 759 assets Other assets 5,567 4,906 Total assets $ 656,032 $ 615,690 Liabilities and stockholders’ equity Current liabilities: Accounts $ 4,159 $ 3,646 payable Accrued 26,686 29,411 expenses Acquisition-r… 583 322 obligations Lease liabilities - 3,192 2,944 short-term Total current 34,620 36,323 liabilities Convertible senior notes, 169,317 168,645 net Lease liabilities - 16,342 14,003 long-term Deferred tax 2,167 1,735 liabilities Other long-term 1,455 1,468 liabilities Total 223,901 222,174 liabilities Stockholders’ equity Common stock 245 244 Additional paid-in 238,938 228,407 capital Retained 215,324 184,715 earnings Accumulated other (4,460 ) (2,411 ) comprehensive loss Treasury stock (17,916 ) (17,439 ) Total stockholders’ 432,131 393,516 equity Total liabilities and $ 656,032 $ 615,690 stockholders’ equity
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (amounts in thousands, except per share amounts) (unaudited)
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (amounts in thousands) (unaudited)
For the nine September 30, September 30, months ended 2026 2025 ────────────────────────────────────────────────────────────────────────────── Operating activities Net income $ 47,753 $ 42,152 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and 8,170 7,813 amortization Stock-based 6,056 5,730 compensation Amortization of issuance costs on 672 653 convertible notes Non-cash investment (253 ) — income Provision for inventory 2,548 1,893 write-downs Provision for 675 455 credit losses Foreign currency transaction 316 (79 ) effect on income Changes in operating assets and liabilities: Accounts (3,347 ) (1,403 ) receivables Inventory and other deferred (3,584 ) (6,805 ) costs Prepaid expenses and (4,244 ) 1,639 other assets Accounts payable and (636 ) 5,327 other liabilities Accrued (1,078 ) 719 interest Net cash provided by 53,048 58,094 operating activities Investing activities Purchases of short-term (390,987 ) (43,015 ) marketable securities Purchases of property and (7,429 ) (5,006 ) equipment Payments related to acquisitions, (194 ) (95 ) net of cash acquired Proceeds from short-term 358,201 — marketable securities Net cash used in investing (40,409 ) (48,116 ) activities Financing activities Proceeds from stock option 4,473 4,657 exercises Deferred payments for (95 ) (1,433 ) acquisitions Payment of withholding taxes in connection (477 ) (605 ) with net settlement of equity awards Common stock cash dividend (17,144 ) (13,572 ) paid Net cash used in financing (13,243 ) (10,953 ) activities Effect of exchange rate changes on (147 ) 859 cash and cash equivalents Net (decrease) increase in (751 ) (116 ) cash and cash equivalents Cash and cash equivalents at 28,244 25,610 beginning of period Cash and cash equivalents at $ 27,493 $ 25,494 end of period
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) SELECTED NET SALES INFORMATION (amounts in thousands) (unaudited)
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON- GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON- GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
Reconciliation between GAAP and Non-GAAP sales growth: For the three months ended September 30, 2026 ────────────────────────────────────────────────────────────────────────────── Net sales as reported $ 67,970 Impact of currency exchange rate 439 fluctuations Adjusted net sales $ 68,409 For the three months ended September 30, 2025 Net sales as reported $ 61,046 Adjusted net sales $ 61,046 Adjusted net sales increase for the $ 7,363 12 % three months ended September 30, 2026 Reconciliation between GAAP and Non-GAAP gross margin growth: For the three months ended September 30, 2026 Gross margin as reported 71.7 % Adjusted gross margin 71.7 % For the three months ended September 30, 2025 Gross margin as reported 75.3 % Employee Retention Tax Credit -4.5 % impact Adjusted gross margin 70.8 % Adjusted gross margin increase for the 0.9 % three months ended September 30, 2026 Reconciliation between GAAP and Non-GAAP operating expense growth: For the three months ended September 30, 2026 Operating expense as reported $ 31,010 Adjusted operating expense $ 31,010 For the three months ended September 30, 2025 Operating expense as reported $ 25,643 Employee Retention Tax Credit 667 impact Adjusted operating expense $ 26,310 Adjusted operating expense increase for the three months ended September $ 4,700 18 % 30, 2026 Reconciliation between GAAP and Non-GAAP operating income growth: For the three months ended September 30, 2026 Operating income as reported $ 17,695 Adjusted operating income $ 17,695 For the three months ended September 30, 2025 Operating income as reported $ 20,312 Employee Retention Tax Credit (3,380 ) impact Adjusted operating income $ 16,932 Adjusted operating income increase for the three months ended September $ 763 5 % 30, 2026 Reconciliation between GAAP and Non-GAAP earnings per share growth: For the three months ended September 30, 2026 Earnings per share as reported $ 0.65 Adjusted earnings per share $ 0.65 For the three months ended September 30, 2025 Earnings per share as reported $ 0.75 Employee Retention Tax Credit (0.13 ) impact Adjusted earnings per share $ 0.62 Adjusted earnings per share increase for the three months ended September $ 0.03 5 % 30, 2026
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON- GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
Reconciliation between GAAP and Non-GAAP projected sales growth: For the three months ending December 31, 2026 ────────────────────────────────────────────────────────────────────────────── Net sales per guidance (midpoint) $ 70,900 Impact of currency exchange rate 507 fluctuations Adjusted projected net sales $ 71,407 For the three months ended December 31, 2025 Net sales as reported $ 64,453 Adjusted net sales $ 64,453 Adjusted projected net sales increase for the three months ending December $ 6,954 11 % 31, 2026 Reconciliation between GAAP and Non-GAAP projected sales growth: For the year ending December 31, 2026 Net sales per guidance (midpoint) $ 275,800 Impact of currency exchange rate (1,433 ) fluctuations Adjusted projected net sales $ 274,367 For the year ended December 31, 2025 Net sales as reported $ 249,602 Net impact of divestitures excluding (1,839 ) currency Adjusted net sales $ 247,763 Adjusted projected net sales increase $ 26,604 11 % for the year ending December 31, 2026 Reconciliation between GAAP and Non-GAAP projected operating income growth: For the year ending December 31, 2026 Operating income per guidance $ 75,400 (midpoint) Projected operating income $ 75,400 For the year ended December 31, 2025 Operating income as reported $ 67,912 Impact of employee retention credit (3,380 ) Adjusted operating income $ 64,532 Adjusted projected operating income increase for the year ending $ 10,868 17 % December 31, 2026 Reconciliation between GAAP and Non-GAAP earnings per share growth: For the year ending December 31, 2026 Earnings per share per guidance $ 2.80 (midpoint) Projected earnings per share $ 2.80 For the year ended December 31, 2025 Earnings per share as reported $ 2.52 Impact of employee retention credit (0.14 ) Adjusted earnings per share $ 2.38 Adjusted projected earnings per share increase for the year ending $ 0.42 18 % December 31, 2026
Full text with the tables
Exhibit 99.1 LeMaitre Q3 2026 Financial Results BURLINGTON, MA, November 4, 2026
– LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices,
implants, and services, today reported Q3 2026 results, announced a quarterly
dividend of $0.25/share, and provided guidance. Q3 2026:
• Sales $68.0mm, +11% (+12% organic) vs. Q3 2025
• Gross margin 71.7% (-360bps, +90 bps vs. adjusted)
• Op. expenses $31.0mm (+21%, +18% vs. adjusted)
• Op. income $17.7mm (-13%, +5% vs. adjusted)
• Op. margin 26%
• EPS $0.65 (-14%, +5% vs. adjusted)
• Cash up $13.5mm sequentially to $390mm at 9/30/2026
Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%.
EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was
comprised of 7% price and 5% units. Gross margin of 71.7% was up 90 bps (vs.
adjusted) due to higher ASPs and operational efficiencies. Operating expenses
increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678
increased 7% versus 9/30/2025 while rep count increased 13% to 171. In October,
the company acquired certain vascular assets from B. Braun for $19.2mm. These
polyester and silver-coated grafts, valve cutters and vein strippers recorded
sales of $9.4mm in 2025, all outside of North America. Sales will transition
into LeMaitre’s channel over the next 18-24months as B. Braun’s customer
contracts conclude or transfer to LeMaitre. During this transition, LeMaitre
will receive a portion of the profits on B. Braun-originated sales. Chairman/CEO
George LeMaitre said, “We expect 2026 to be another year of healthy sales (+11%)
and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s
international launch and the continued growth of RestoreFlow Allografts. The
acquired B. Braun products will strengthen our core vascular portfolio while
leveraging our expanding 31-countrysales force.” Business Outlook
Q4 2026 Guidance Full Year 2026 Guidance
$69.9mm - $71.9mm $274.8mm - $276.8mm
Sales (Mid $70.9mm, +10%, +11% (Mid $275.8mm, +11%, +11%
org.) org.)
Gross Margin 72.1% 72.1%
$18.8mm - $20.2mm $74.6mm - $76.1mm
Op. Income (Mid $19.5mm, +4%) (Mid $75.4mm, +11%, +17%
adj.)
Op. Margin (Mid) 27% 27%
$0.70 - $0.75 $2.77 - $2.82
EPS (Mid $0.73, +7%) (Mid $2.80, +11%, +18%
adj.)
The top- and bottom-line impacts of the newly acquired B. Braun
* products are reflected in this Business Outlook. LeMaitre anticipates
recording ~$150,000 of Q4 2026 B. Braun product sales and break-even
operating income impact.
2025 results include a Q3 non-recurring benefit from the Employee
** Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A
reconciliation of GAAP to non-GAAP measures is included.
Quarterly Dividend On October 27, 2026, the Company’s Board of Directors
approved a quarterly dividend of $0.25/share of common stock. The dividend will
be paid on December 3, 2026, to stockholders of record on November 19, 2026.
Share Repurchase Program On February 19, 2026, the Company’s Board of Directors
authorized the repurchase of up to $100.0mm of the Company’s common stock. The
repurchase program may be suspended or discontinued at any time and will
conclude on February 18, 2027, unless extended by the Board.
Conference Call Reminder
Management will conduct a conference call at 5:00pm ET today. The conference
call will be broadcast live over the Internet. Individuals interested in
listening to the webcast can log on to the Company’s website at . Access to the
live call is available by registering online . All registrants will receive
dial-in information and a PIN allowing them to access the live call. The audio
webcast can also be accessed live or via replay through a webcast at . For
individuals unable to
join the live conference call, a replay will be available on the Company’s
website.
A reconciliation of GAAP to
non-GAAP results is included in the tables attached to this release.
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of
peripheral vascular disease, a condition that affects more than
200 million people worldwide. The Company develops, manufactures, and markets
disposable and implantable vascular devices to address the needs of its core
customer, the vascular surgeon.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release
may include other trademarks and trade names of the Company.
For more information about the Company, please visit .
Use of Non-GAAPFinancial Measures
LeMaitre management believes that in order to better understand the Company’s
short- and long-term financial trends, investors may wish to consider
certain non-GAAP financial measures as a supplement to financial performance
measures prepared in accordance with GAAP. Non-GAAP financial measures are not
based on a
comprehensive set of accounting rules or principles and do not have standardized
meanings. These non-GAAP measures result from facts and circumstances that may
vary in frequency and/or impact on continuing
operations. Non-GAAP measures should be considered in addition to, and not as a
substitute for, GAAP financial performance measures. In addition to the
description provided below, reconciliation of GAAP to non-GAAP results is
provided in the financial statement tables included in this press release.
In this press release,
the Company has reported non-GAAP sales growth percentages after adjusting for
the impact of foreign currency exchange, business development transactions,
and/or other events. The Company refers to the
calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The
Company analyzes non-GAAP sales on a constant currency basis,
net of acquisitions and other non-recurring events. Because changes in foreign
currency exchange rates have a non-operating impact on net sales, and
acquisitions,
divestitures, product discontinuations, factory closures, and other strategic
transactions are episodic in nature and are highly variable to the reported
sales results, the Company believes that evaluating growth in sales on a
constant currency
basis net of such transactions provides an additional and meaningful assessment
of sales to management. Additionally, the Company has provided percentages for
Q3 2026 operating income, gross margin, operating expense and EPS, as well as
operating
income and EPS guidance, adjusted to exclude the effects of the employee
retention tax credit received in 2025. Management believes that viewing growth
in these measures excluding those effects provides an alternative and meaningful
view of the
Company’s profitability.
Investors are encouraged to review the reconciliation of these non-GAAP
financial
measures to their most directly comparable GAAP financial measures set forth in
the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures”
below.
Forward-Looking Statements
The Company’s current
financial results, as discussed in this release, are preliminary and unaudited,
and subject to adjustment. This press release contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995.
Statements in this press release regarding the Company’s business that are not
historical facts may be “forward-looking statements” that involve risks and
uncertainties. Forward-looking statements are based on management’s
current, preliminary expectations and are subject to risks and uncertainties
that could cause actual results to differ from the results expected, including,
but not limited to, our ability to maintain historic levels of profit growth;
our ability to
increase the selling prices of our products; the status of our regulatory
approvals, compliance with regulatory requirements, and the potential for
adverse regulatory findings or enforcement actions arising from inspections,
audits, or other
regulatory reviews, affecting our ability to market and sell our products
domestically and internationally; our ability to source, acquire, and integrate
acquisitions; our dependence on sole- or limited-source suppliers; competition
from other
medical device companies and alternative medical technologies; our ability to
engage sales call points other than vascular surgeons; disruptions to our
information technology systems or breaches of our information security systems;
our
implementation of our new enterprise resource planning system; our ability to
procure, process, and preserve human tissue and comply with relevant regulatory
requirements; the impact of a disruption in our manufacturing facilities; our
ability to
navigate the risks inherent in operating internationally; our ability to
transition to direct sales models in certain international territories; the
occurrence of
litigation relating to product liability, employment matters, intellectual
property, contract disputes, and other matters; the occurrence of product
defects or recalls; our ability to service and
repurchase our debt; the dilutive effect of a conversion of our debt; our
ability to navigate executive officer transitions and retain key personnel; our
ability to protect our intellectual property; volatility in the price of our
common stock; and
other risks and uncertainties included under the heading “Risk Factors” in our
most recent Annual Report on Form 10-K, as updated by our subsequent filings
with the SEC, which are all
available on the Company’s investor relations website at http://www.lemaitre.com
and on the SEC’s website at http://www.sec.gov. Undue reliance should not be
placed on forward-looking statements, which speak only
as of the date they are made. The Company undertakes no obligation to update
publicly any forward-looking statements to reflect new information, events, or
circumstances after the date they were made, or to reflect the occurrence of
unanticipated
events.
Contact:
[email protected]
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
-unaudited
Assets
Current
assets:
Cash and cash $ 27,493 $ 28,244
equivalents
Short-term
marketable 362,228 330,876
securities
Accounts
receivable, 35,876 33,610
net
Inventory and
other deferred 71,272 70,422
costs
Prepaid
expenses and 8,642 5,080
other current
assets
Total current 505,511 468,232
assets
Property and 30,465 26,997
equipment, net
Right-of-use 18,503 15,762
leased assets
Goodwill 65,945 65,945
Other
intangibles, 29,295 33,089
net
Deferred tax 746 759
assets
Other assets 5,567 4,906
Total assets $ 656,032 $ 615,690
Liabilities
and
stockholders’
equity
Current
liabilities:
Accounts $ 4,159 $ 3,646
payable
Accrued 26,686 29,411
expenses
Acquisition-r… 583 322
obligations
Lease
liabilities - 3,192 2,944
short-term
Total current 34,620 36,323
liabilities
Convertible
senior notes, 169,317 168,645
net
Lease
liabilities - 16,342 14,003
long-term
Deferred tax 2,167 1,735
liabilities
Other
long-term 1,455 1,468
liabilities
Total 223,901 222,174
liabilities
Stockholders’
equity
Common stock 245 244
Additional
paid-in 238,938 228,407
capital
Retained 215,324 184,715
earnings
Accumulated
other (4,460 ) (2,411 )
comprehensive
loss
Treasury stock (17,916 ) (17,439 )
Total
stockholders’ 432,131 393,516
equity
Total
liabilities
and $ 656,032 $ 615,690
stockholders’
equity
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF
OPERATIONS (amounts in thousands, except per share amounts) (unaudited)
For For
the the
three Sept… Septe… nine Septe… Sept…
months 30, 30, mont… 30, 30,
ended 2026 2025 ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 67,9… $ 61,046 $ 204,9… $ 185,…
sales
Cost
of 19,2… 15,091 57,038 52,8…
sales
Gross 48,7… 45,955 147,8… 132,…
prof…
Oper…
expe…
Sales
and 14,5… 11,923 43,429 41,0…
mark…
Gene…
and 12,0… 10,750 35,239 31,6…
admi…
Rese…
and 4,421 2,970 13,328 10,6…
deve…
Total
oper… 31,0… 25,643 91,996 83,2…
expe…
Inco…
from 17,6… 20,312 55,869 49,0…
oper…
Other
inco…
(exp…
Inve… 3,365 3,864 10,075 9,747
inco…
Inte… (1,3… ) (1,297 ) (3,906 ) (3,8… )
expe…
Other
inco… (82 ) (306 ) (503 ) (57 )
(los…
net
Inco…
befo… 19,6… 22,573 61,535 54,8…
inco…
taxes
Prov…
for 4,650 5,211 13,782 12,7…
inco…
taxes
Net $ 15,0… $ 17,362 $ 47,753 $ 42,1…
inco…
Earn…
per
share
of
comm…
stock
Basic $ 0.66 $ 0.77 $ 2.09 $ 1.86
Dilu… $ 0.65 $ 0.75 $ 2.07 $ 1.84
Weig…
-
aver…
shar…
outs…
Basic 22,8… 22,660 22,844 22,6…
Dilu… 23,0… 24,392 23,064 22,9…
Cash
divi…
decl… $ 0.25 $ 0.20 $ 0.75 $ 0.60
per
comm…
share
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) CONDENSED CONSOLIDATED STATEMENT OF CASH
FLOWS (amounts in thousands) (unaudited)
For the nine September 30, September 30,
months ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Operating
activities
Net income $ 47,753 $ 42,152
Adjustments to
reconcile net
income to
net cash
provided by
operating
activities
Depreciation
and 8,170 7,813
amortization
Stock-based 6,056 5,730
compensation
Amortization
of issuance
costs on 672 653
convertible
notes
Non-cash
investment (253 ) —
income
Provision for
inventory 2,548 1,893
write-downs
Provision for 675 455
credit losses
Foreign
currency
transaction 316 (79 )
effect on
income
Changes in
operating
assets and
liabilities:
Accounts (3,347 ) (1,403 )
receivables
Inventory and
other deferred (3,584 ) (6,805 )
costs
Prepaid
expenses and (4,244 ) 1,639
other assets
Accounts
payable and (636 ) 5,327
other
liabilities
Accrued (1,078 ) 719
interest
Net cash
provided by 53,048 58,094
operating
activities
Investing
activities
Purchases of
short-term (390,987 ) (43,015 )
marketable
securities
Purchases of
property and (7,429 ) (5,006 )
equipment
Payments
related to
acquisitions, (194 ) (95 )
net of
cash acquired
Proceeds from
short-term 358,201 —
marketable
securities
Net cash used
in investing (40,409 ) (48,116 )
activities
Financing
activities
Proceeds from
stock option 4,473 4,657
exercises
Deferred
payments for (95 ) (1,433 )
acquisitions
Payment of
withholding
taxes in
connection (477 ) (605 )
with net
settlement of
equity
awards
Common stock
cash dividend (17,144 ) (13,572 )
paid
Net cash used
in financing (13,243 ) (10,953 )
activities
Effect of
exchange rate
changes on (147 ) 859
cash
and cash
equivalents
Net (decrease)
increase in (751 ) (116 )
cash and cash
equivalents
Cash and cash
equivalents at 28,244 25,610
beginning
of period
Cash and cash
equivalents at $ 27,493 $ 25,494
end of
period
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) SELECTED NET SALES INFORMATION (amounts
in thousands) (unaudited)
… …
… …
… … … … … …
… … … … … …
… … … … … …
──────────────────────────────────────────────────────────────────────────────
$ % $ % $ % $ %
$ … … % $ … … % $ … … % $ … … %
… … % … … % … … % … … %
… 6 % … 7 % … 7 % … 7 %
$ … … % $ … … % $ … … % $ … … %
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON-
GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
For For
the the
three Sept… Septe… nine Septe… Sept…
months 30, 30, mont… 30, 30,
ended 2026 2025 ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Reco…
betw…
GAAP
Net
Inco…
and
Non-…
Adju…
EBIT…
Net
inco… $ 15,0… $ 17,362 $ 47,753 $ 42,1…
as
repo…
Empl…
rete…
tax — (3,380 ) — (3,3… )
cred…
net
Inte…
(inc… (2,0… ) (2,567 ) (6,169 ) (5,8… )
expe…
net
Amor…
and 2,885 2,612 8,170 7,812
depr…
expe…
Prov…
for 4,650 5,211 13,782 12,7…
inco…
taxes
Adju… $ 20,4… $ 19,238 $ 63,536 $ 53,4…
EBIT…
Adju…
EBIT… 7 % 19 %
perc…
incr…
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON-
GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
Reconciliation between GAAP and
Non-GAAP sales
growth:
For the three months ended
September 30, 2026
──────────────────────────────────────────────────────────────────────────────
Net sales as reported $ 67,970
Impact of currency exchange rate 439
fluctuations
Adjusted net sales $ 68,409
For the three months ended
September 30,
2025
Net sales as reported $ 61,046
Adjusted net sales $ 61,046
Adjusted net sales increase for
the $ 7,363 12 %
three months ended September 30,
2026
Reconciliation between GAAP and
Non-GAAP gross margin
growth:
For the three months ended
September 30,
2026
Gross margin as reported 71.7 %
Adjusted gross margin 71.7 %
For the three months ended
September 30,
2025
Gross margin as reported 75.3 %
Employee Retention Tax Credit -4.5 %
impact
Adjusted gross margin 70.8 %
Adjusted gross margin increase for
the 0.9 %
three months ended September 30,
2026
Reconciliation between GAAP and
Non-GAAP operating expense
growth:
For the three months ended
September 30,
2026
Operating expense as reported $ 31,010
Adjusted operating expense $ 31,010
For the three months ended
September 30,
2025
Operating expense as reported $ 25,643
Employee Retention Tax Credit 667
impact
Adjusted operating expense $ 26,310
Adjusted operating expense
increase for
the three months ended September $ 4,700 18 %
30,
2026
Reconciliation between GAAP and
Non-GAAP operating income
growth:
For the three months ended
September 30,
2026
Operating income as reported $ 17,695
Adjusted operating income $ 17,695
For the three months ended
September 30,
2025
Operating income as reported $ 20,312
Employee Retention Tax Credit (3,380 )
impact
Adjusted operating income $ 16,932
Adjusted operating income increase
for
the three months ended September $ 763 5 %
30,
2026
Reconciliation between GAAP and
Non-GAAP earnings per
share growth:
For the three months ended
September 30,
2026
Earnings per share as reported $ 0.65
Adjusted earnings per share $ 0.65
For the three months ended
September 30,
2025
Earnings per share as reported $ 0.75
Employee Retention Tax Credit (0.13 )
impact
Adjusted earnings per share $ 0.62
Adjusted earnings per share
increase for
the three months ended September $ 0.03 5 %
30,
2026
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) RECONCILIATION OF GAAP TO NON-
GAAPFINANCIAL MEASURES (amounts in thousands) (unaudited)
Reconciliation between GAAP and
Non-GAAP projected sales
growth:
For the three months ending December
31, 2026
──────────────────────────────────────────────────────────────────────────────
Net sales per guidance (midpoint) $ 70,900
Impact of currency exchange rate 507
fluctuations
Adjusted projected net sales $ 71,407
For the three months ended December
31,
2025
Net sales as reported $ 64,453
Adjusted net sales $ 64,453
Adjusted projected net sales
increase
for the three months ending December $ 6,954 11 %
31,
2026
Reconciliation between GAAP and
Non-GAAP projected sales
growth:
For the year ending December 31,
2026
Net sales per guidance (midpoint) $ 275,800
Impact of currency exchange rate (1,433 )
fluctuations
Adjusted projected net sales $ 274,367
For the year ended December 31, 2025
Net sales as reported $ 249,602
Net impact of divestitures excluding (1,839 )
currency
Adjusted net sales $ 247,763
Adjusted projected net sales
increase $ 26,604 11 %
for the year ending December 31,
2026
Reconciliation between GAAP and
Non-GAAP projected
operating income growth:
For the year ending December 31,
2026
Operating income per guidance $ 75,400
(midpoint)
Projected operating income $ 75,400
For the year ended December 31, 2025
Operating income as reported $ 67,912
Impact of employee retention credit (3,380 )
Adjusted operating income $ 64,532
Adjusted projected operating income
increase for the year ending $ 10,868 17 %
December
31, 2026
Reconciliation between GAAP and
Non-GAAP earnings per
share growth:
For the year ending December 31,
2026
Earnings per share per guidance $ 2.80
(midpoint)
Projected earnings per share $ 2.80
For the year ended December 31, 2025
Earnings per share as reported $ 2.52
Impact of employee retention credit (0.14 )
Adjusted earnings per share $ 2.38
Adjusted projected earnings per
share
increase for the year ending $ 0.42 18 %
December
31, 2026